Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis

Recruiting now · Early Phase 1

Conditions studied: Chronic Kidney Diseases, Calciphylaxis, Calcific Uremic Arteriolopathy, Treatment, Safety, Efficacy

In brief

Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells

Key facts

Study ID

NCT04592640

Run by

The First Affiliated Hospital with Nanjing Medical University

People needed

9

Starts

2018-09-17

Expected to finish

2028-09-17

Last updated by the study team

2026-03-04

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18-75 years old.
• Clinical diagnosis of calciphylaxis, including patients with chronic kidney disease who did not or had regular dialysis (hemodialysis or peritoneal dialysis).
• All subjects signed informed consent.

You may not qualify if…

• Patients who refuse to sign informed consent.
• Patients with malignant tumors or severe psychiatric disorders, or an expected survival time of less than 6 months.
• Pregnant or lactating women of childbearing age.
• Participation in another clinical trial with an experimental drug within 90 days prior the inclusion.

Where it is running

• The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital — Nanjing, Jiangsu, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.